The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma
Open Access
- 5 July 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 21 (9), 1875-1884
- https://doi.org/10.1038/sj.leu.2404843
Abstract
Immunomodulatory drugs (IMiDs) and bortezomib have been recently used in the management of patients with both newly diagnosed and relapsed/refractory multiple myeloma. Except of their direct anti-myeloma effect, these agents also alter the interactions between myeloma cells and marrow microenvironment. Several recent studies have investigated their potential effect on myeloma bone disease. Preclinical studies have demonstrated that IMiDs reduce osteoclast formation and function in vitro. Clinical studies have confirmed that thalidomide reduces markers of bone resorption, while lenalidomide induces osteoclast arrest in myeloma patients. However, IMiDs seem to have no effect on osteoblast exhaustion present in myeloma. The proteasome inhibitor bortezomib restores abnormal bone remodeling through the inhibition of osteoclast function and the increase in osteoblast differentiation and activity in vitro. In myeloma patients, bortezomib reduces biochemical markers of bone resorption and normalizes the RANKL/osteoprotegerin ratio, while at the same time increases bone formation markers reducing levels of dickkopf-1 protein. Whether these effects are direct and not only a consequence of the agents' antimyeloma activity is not totally clear. This review summarizes all available data for these attractive agents that combine potent anti-myeloma activity with beneficial effects on bone and may alter the way of management of myeloma-related bone disease.Keywords
This publication has 91 references indexed in Scilit:
- Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus StatementMayo Clinic Proceedings, 2007
- Myeloma Cell-Osteoclast Interaction Enhances Angiogenesis Together with Bone Resorption: A Role for Vascular Endothelial Cell Growth Factor and OsteopontinClinical Cancer Research, 2007
- Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor CellsCancer Research, 2007
- A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaBlood, 2006
- Thalidomide and lenalidomide in the treatment of multiple myelomaEuropean Journal Of Cancer, 2006
- Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone diseaseBiochemical and Biophysical Research Communications, 2005
- Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic AcidJournal of Clinical Oncology, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Proteasome inhibitors abrogate osteoclast differentiation and osteoclast functionBiochemical and Biophysical Research Communications, 2005
- Tartrate‐resistant acid phosphatase isoform 5b: A novel serum marker for monitoring bone disease in multiple myelomaInternational Journal of Cancer, 2003